The FDA’s approval of Kisunla demonstrates a positive change in Alzheimer disease management. Offering illness pathology therapy and the option of treatment conclusion after reaching therapeutic goals ...
GE HealthCare’s recently acquired MIM Software division has secured an FDA clearance for a tool to help quantify the density ...
A study published Wednesday in Nature Neuroscience sheds light into how amyloid-beta and tau proteins impact brain activity ...
2don MSN
Boosting a certain brain protein could help slow the progression of Alzheimer’s disease, a new study has found. The ...
The GE HealthCare imaging tool is coming out as pharma companies release new therapies onto the market to help treat the ...
Kisunla (donanemab-azbt) is a brand-name injection for IV infusion that’s prescribed for certain types of Alzheimer’s disease in adults. As with other drugs, Kisunla can cause side effects ...
Kisunla (donanemab-azbt) is a brand-name injection for IV infusion prescribed for Alzheimer’s disease. Kisunla has no known interactions with alcohol, other drugs, or supplements. However ...
Kisunla (donanemab-azbt) is a prescription drug used to treat Alzheimer’s disease. The drug is given as an intravenous (IV) infusion by a healthcare professional. You’ll typically receive a ...
Researchers have discovered that Alzheimer's drugs Leqembi and Kisunla boost levels of a healthy form of protein in the brain, even as they reduce its more toxic form.
A CareSouth Carolina patient is among the first in the United States to receive a groundbreaking treatment aimed at slowing ...
The next generation of Alzheimer’s therapeutics is moving away from amyloid plaques and tau tangles, offering multiple ...
Two years ago, almost to the day, I lost my mother to Alzheimer’s disease, which took us both through six trying years. With ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback